Abstract
A guidance of the Food and Drug Administration (FDA) recommends that the pharmacodynamic (PD) equivalence of topical corticosteroid preparations be demonstrated by a two-step procedure. A pilot study would establish the ED50 of a PD relationship between dose duration and a vasoconstrictor response. The relevance of the assumed hyperbolic Michaelis-Menten response model is evaluated by both graphical exploratory and population PD analyses of the data presented in the guidance. It is shown that the observations are far removed from their asymptotic plateau, and that they can be characterized well by a simplified Hill equation with a Hill coefficient of 0.4. Consequently, it is suggested that pilot studies are not needed when the dose range for sensitive responses is known. Nonresponding subjects should be removed from the analyses of both stages of an investigation. PD equivalence should be assessed with dose durations distanced as far as possible from each other. Finally, the study demonstrates the usefulness of graphical, exploratory analyses without which modeling by regression, including population kinetic and PD computations, can be misinterpreted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.